drugset / Trial / NCT01736696

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

NCT01736696

Phase 1 Completed 59 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

Timeline

Start
2002-11
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg
Subject Tofacitinib Small molecule 10 mg
Subject Tofacitinib Small molecule 20 mg
Subject Tofacitinib Small molecule 30 mg
Subject Tofacitinib Small molecule 50 mg
Subject Tofacitinib Small molecule 60 mg

Indications